TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:TAK - US8740602052 - ADR
16.01 USD
-0.25 (-1.54%)
16.01 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to TAK. TAK was compared to 190 industry peers in the Pharmaceuticals industry. TAK has an excellent profitability rating, but there are concerns on its financial health. TAK has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
TAK had positive earnings in the past year.
In the past year TAK had a positive cash flow from operations.
In the past 5 years TAK has always been profitable.
In the past 5 years TAK always reported a positive cash flow from operatings.
1.2 Ratios
TAK has a better Return On Assets (0.23%) than 77.89% of its industry peers.
TAK has a Return On Equity of 0.46%. This is in the better half of the industry: TAK outperforms 79.47% of its industry peers.
Looking at the Return On Invested Capital, with a value of 1.87%, TAK is in the better half of the industry, outperforming 78.95% of the companies in the same industry.
TAK had an Average Return On Invested Capital over the past 3 years of 2.62%. This is significantly below the industry average of 12.84%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.23% | ||
| ROE | 0.46% | ||
| ROIC | 1.87% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
1.3 Margins
TAK has a Profit Margin of 0.75%. This is in the better half of the industry: TAK outperforms 77.89% of its industry peers.
In the last couple of years the Profit Margin of TAK has grown nicely.
TAK's Operating Margin of 8.46% is fine compared to the rest of the industry. TAK outperforms 80.00% of its industry peers.
In the last couple of years the Operating Margin of TAK has grown nicely.
The Gross Margin of TAK (64.60%) is better than 74.21% of its industry peers.
In the last couple of years the Gross Margin of TAK has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.46% | ||
| PM (TTM) | 0.75% | ||
| GM | 64.6% |
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so TAK is still creating some value.
The number of shares outstanding for TAK has been increased compared to 1 year ago.
The number of shares outstanding for TAK has been increased compared to 5 years ago.
TAK has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.23, we must say that TAK is in the distress zone and has some risk of bankruptcy.
TAK's Altman-Z score of 1.23 is in line compared to the rest of the industry. TAK outperforms 53.68% of its industry peers.
TAK has a debt to FCF ratio of 5.04. This is a neutral value as TAK would need 5.04 years to pay back of all of its debts.
TAK's Debt to FCF ratio of 5.04 is amongst the best of the industry. TAK outperforms 83.16% of its industry peers.
TAK has a Debt/Equity ratio of 0.61. This is a neutral value indicating TAK is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.61, TAK is doing worse than 68.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 5.04 | ||
| Altman-Z | 1.23 |
ROIC/WACC1.16
WACC1.62%
2.3 Liquidity
A Current Ratio of 1.36 indicates that TAK should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.36, TAK is doing worse than 74.21% of the companies in the same industry.
TAK has a Quick Ratio of 1.36. This is a bad value and indicates that TAK is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.76, TAK is doing worse than 84.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.76 |
3. Growth
3.1 Past
The earnings per share for TAK have decreased strongly by -88.38% in the last year.
The Earnings Per Share has been growing by 19.20% on average over the past years. This is quite good.
TAK shows a decrease in Revenue. In the last year, the revenue decreased by -2.84%.
Measured over the past years, TAK shows a small growth in Revenue. The Revenue has been growing by 6.84% on average per year.
EPS 1Y (TTM)-88.38%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%-112.87%
Revenue 1Y (TTM)-2.84%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%-5.38%
3.2 Future
TAK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.97% yearly.
Based on estimates for the next years, TAK will show a decrease in Revenue. The Revenue will decrease by -0.03% on average per year.
EPS Next Y83.65%
EPS Next 2Y68.19%
EPS Next 3Y43.97%
EPS Next 5YN/A
Revenue Next Year-1.77%
Revenue Next 2Y-0.66%
Revenue Next 3Y-0.03%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 228.71, TAK can be considered very expensive at the moment.
TAK's Price/Earnings ratio is a bit cheaper when compared to the industry. TAK is cheaper than 75.26% of the companies in the same industry.
TAK's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.30.
Based on the Price/Forward Earnings ratio of 26.15, the valuation of TAK can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TAK indicates a somewhat cheap valuation: TAK is cheaper than 74.21% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of TAK to the average of the S&P500 Index (24.04), we can say TAK is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 228.71 | ||
| Fwd PE | 26.15 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, TAK is valued cheaper than 88.42% of the companies in the same industry.
92.63% of the companies in the same industry are more expensive than TAK, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.65 | ||
| EV/EBITDA | 10.7 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
TAK has a very decent profitability rating, which may justify a higher PE ratio.
TAK's earnings are expected to grow with 43.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.73
PEG (5Y)11.91
EPS Next 2Y68.19%
EPS Next 3Y43.97%
5. Dividend
5.1 Amount
TAK has a Yearly Dividend Yield of 3.93%. Purely for dividend investing, there may be better candidates out there.
TAK's Dividend Yield is rather good when compared to the industry average which is at 0.35. TAK pays more dividend than 96.84% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 1.92, TAK pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.93% |
5.2 History
The dividend of TAK has a limited annual growth rate of 1.18%.
TAK has been paying a dividend for at least 10 years, so it has a reliable track record.
TAK has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.18%
Div Incr Years2
Div Non Decr Years3
5.3 Sustainability
TAK pays out 935.06% of its income as dividend. This is not a sustainable payout ratio.
The dividend of TAK is growing, but earnings are growing more, so the dividend growth is sustainable.
DP935.06%
EPS Next 2Y68.19%
EPS Next 3Y43.97%
16.01
-0.25 (-1.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners47.21%
Inst Owner Change-0.01%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap50.58B
Revenue(TTM)4.42T
Net Income(TTM)33.08B
Analysts74.44
Price Target16.52 (3.19%)
Short Float %0.37%
Short Ratio4.12
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.93% |
Yearly Dividend0.61
Dividend Growth(5Y)1.18%
DP935.06%
Div Incr Years2
Div Non Decr Years3
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-41.49%
Min EPS beat(2)-121.92%
Max EPS beat(2)38.94%
EPS beat(4)1
Avg EPS beat(4)-35.42%
Min EPS beat(4)-121.92%
Max EPS beat(4)38.94%
EPS beat(8)4
Avg EPS beat(8)-31.47%
EPS beat(12)6
Avg EPS beat(12)-33.69%
EPS beat(16)7
Avg EPS beat(16)-40.61%
Revenue beat(2)0
Avg Revenue beat(2)-6.4%
Min Revenue beat(2)-6.76%
Max Revenue beat(2)-6.04%
Revenue beat(4)0
Avg Revenue beat(4)-3.84%
Min Revenue beat(4)-6.76%
Max Revenue beat(4)-0.48%
Revenue beat(8)4
Avg Revenue beat(8)3.03%
Revenue beat(12)7
Avg Revenue beat(12)3.44%
Revenue beat(16)11
Avg Revenue beat(16)3.69%
PT rev (1m)1.64%
PT rev (3m)-6.4%
EPS NQ rev (1m)16.95%
EPS NQ rev (3m)18.24%
EPS NY rev (1m)-6.66%
EPS NY rev (3m)-18.71%
Revenue NQ rev (1m)0.25%
Revenue NQ rev (3m)1.67%
Revenue NY rev (1m)-0.24%
Revenue NY rev (3m)-0.68%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 228.71 | ||
| Fwd PE | 26.15 | ||
| P/S | 1.81 | ||
| P/FCF | 8.65 | ||
| P/OCF | 6.65 | ||
| P/B | 1.12 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.7 |
EPS(TTM)0.07
EY0.44%
EPS(NY)0.61
Fwd EY3.82%
FCF(TTM)1.85
FCFY11.56%
OCF(TTM)2.41
OCFY15.04%
SpS8.86
BVpS14.31
TBVpS-3.21
PEG (NY)2.73
PEG (5Y)11.91
Graham Number4.75
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.23% | ||
| ROE | 0.46% | ||
| ROCE | 3.03% | ||
| ROIC | 1.87% | ||
| ROICexc | 1.99% | ||
| ROICexgc | 8.07% | ||
| OM | 8.46% | ||
| PM (TTM) | 0.75% | ||
| GM | 64.6% | ||
| FCFM | 20.88% |
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.62%
ROIC(5y)2.55%
ROICexc(3y)2.76%
ROICexc(5y)2.73%
ROICexgc(3y)14.61%
ROICexgc(5y)14.15%
ROCE(3y)4.25%
ROCE(5y)4.14%
ROICexgc growth 3Y-6.2%
ROICexgc growth 5Y8.09%
ROICexc growth 3Y-3.88%
ROICexc growth 5Y10.72%
OM growth 3Y-8.47%
OM growth 5Y6.13%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
F-Score6
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 5.04 | ||
| Debt/EBITDA | 3.9 | ||
| Cap/Depr | 37.3% | ||
| Cap/Sales | 6.28% | ||
| Interest Coverage | 3.04 | ||
| Cash Conversion | 107.4% | ||
| Profit Quality | 2788.5% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.76 | ||
| Altman-Z | 1.23 |
F-Score6
WACC1.62%
ROIC/WACC1.16
Cap/Depr(3y)69.03%
Cap/Depr(5y)56.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)9.44%
Profit Quality(3y)309.71%
Profit Quality(5y)308.48%
High Growth Momentum
Growth
EPS 1Y (TTM)-88.38%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%-112.87%
EPS Next Y83.65%
EPS Next 2Y68.19%
EPS Next 3Y43.97%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.84%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%-5.38%
Revenue Next Year-1.77%
Revenue Next 2Y-0.66%
Revenue Next 3Y-0.03%
Revenue Next 5YN/A
EBIT growth 1Y-31.07%
EBIT growth 3Y-0.52%
EBIT growth 5Y13.39%
EBIT Next Year435.35%
EBIT Next 3Y77.31%
EBIT Next 5YN/A
FCF growth 1Y613.62%
FCF growth 3Y-8.86%
FCF growth 5Y9.4%
OCF growth 1Y24.54%
OCF growth 3Y-2%
OCF growth 5Y9.54%
TAKEDA PHARMACEUTIC-SP ADR / TAK FAQ
What is the fundamental rating for TAK stock?
ChartMill assigns a fundamental rating of 5 / 10 to TAK.
What is the valuation status for TAK stock?
ChartMill assigns a valuation rating of 5 / 10 to TAKEDA PHARMACEUTIC-SP ADR (TAK). This can be considered as Fairly Valued.
What is the profitability of TAK stock?
TAKEDA PHARMACEUTIC-SP ADR (TAK) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for TAK stock?
The Price/Earnings (PE) ratio for TAKEDA PHARMACEUTIC-SP ADR (TAK) is 228.71 and the Price/Book (PB) ratio is 1.12.
How financially healthy is TAKEDA PHARMACEUTIC-SP ADR?
The financial health rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) is 3 / 10.